Internet Archive Scholar

Phase II Trial of Busulfan-Based Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed By Reduced Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma

Yi-Bin Chen, Shuli Li, Candice Del Rio, Jessica Driscoll, Hossein Sadrzadeh, Jeremy S. Abramson, Philippe Armand, Jeffrey Barnes, Corey S. Cutler, David C. Fisher, Vincent T. Ho, Ephraim Hochberg (+5 others)
2014 Biology of Blood and Marrow Transplantation  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (225.1 kB)
https://web.archive.org/web/20190328133056/https://core.ac.uk/download/pdf/82483441.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

comorbidity index (HCT-CI) scores > 2 (72% vs 37%, p ¼ 0.009), and pre-NMAT platelets < 25k/uL (33% vs 8%, p ¼ 0.01). In an unadjusted comparison, OS and PFS favored the RIT pts, but the differences were not statistically significant (hazard ratio [HR] for OS ¼ 0.60, 95% confidence interval [CI]: 0.3-1.4, p ¼ 0.24; HR for PFS ¼ 0.75, 95% CI: 0.4-1.5, p ¼ 0.41). However, after adjusting for significant differences between these groups, outcomes for the RIT-treated group were significantly better
more » ... (HR for OS ¼ 0.30; 95% CI: 0.1-0.8, p ¼ 0.007; HR for PFS ¼ 0.42, 95% CI: 0.2-0.9, p ¼ 0.02). With a median follow-up of 81 months in surviving patients, the 3-year adjusted estimates for the RIT and control groups were: OS 87% and 59%, PFS 71% and 44%, respectively (Figures 1 and 2) . Conclusions: These data suggest that the addition of 90 Yibritumomab tiuxetan prior to NMAT may result in improved OS and PFS for patients with persistent iB-NHL. These results set the stage for a prospective randomized comparison of these strategies in this setting.
doi:10.1016/j.bbmt.2013.12.088 fatcat:52wiie7nmzbkdh462hrcsd6nze
Open Access
Citation

Yi-Bin Chen, Shuli Li, Candice Del Rio, Jessica Driscoll, Hossein Sadrzadeh, Jeremy S. Abramson, Philippe Armand, Jeffrey Barnes, Corey S. Cutler, David C. Fisher, Vincent T. Ho, Ephraim Hochberg, Steven L. McAfee, Ronald Takvorian, Joseph H. Antin, Robert J. Soiffer, Eric Jacobsen. "Phase II Trial of Busulfan-Based Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed By Reduced Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma." Biology of Blood and Marrow Transplantation 20.2 (2014) S73